Quince Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Quince Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Quince Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.86M, a 3.79% increase year-over-year.
  • Quince Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$55.3M, a 78.8% decline year-over-year.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$34.6M, a 33.4% increase from 2022.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$52M, a 42.4% increase from 2021.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$90.3M, a 14.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$55.3M -$5.86M +$231K +3.79% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$55.5M -$28.2M -$22.6M -405% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$32.9M -$11.2M +$1.74M +13.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$34.6M -$9.99M -$3.71M -59.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$30.9M -$6.09M +$1.53M +20% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$32.4M -$5.58M +$10.7M +65.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$43.1M -$13M +$8.91M +40.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$52M -$6.27M +$17.3M +73.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$69.3M -$7.62M +$14.1M +64.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$83.3M -$16.3M +$5.53M +25.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$88.9M -$21.9M +$1.45M +6.22% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$90.3M -$23.5M -$2.69M -12.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$87.6M -$21.7M +$235K +1.07% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$87.9M -$21.8M -$3.51M -19.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$84.3M -$23.3M -$5.46M -30.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$78.9M -$20.9M -$7.9M -61% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$71M -$21.9M -$11.3M -107% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$59.6M -$18.3M -$8.7M -90.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$51M -$17.9M -$11.8M -194% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$39.2M -$12.9M -$9.11M -237% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$30.1M -$10.6M -$7.7M -268% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$22.4M -$9.58M -$6.93M -262% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$15.4M -$6.08M -$3.32M -120% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$12.1M -$3.84M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$2.87M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$2.64M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$2.76M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.